Neoplasms Clinical Trial
— ACEOfficial title:
Alberta Cancer Exercise Community-based Program: A Pilot Randomized Controlled Trial
| Verified date | April 2018 |
| Source | University of Alberta |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The purpose of the study is to examine the benefit and specific outcomes of a community-based
exercise program that is designed to address the needs of individuals who are receiving or
recovering from cancer treatment.
Eighty cancer survivors from Edmonton and Calgary will take part in the 24-week long study.
Survivors will be randomly assigned to one of two groups. The first group will take part in
an 8-week supervised exercise program followed by 8 weeks of self-directed or home-based
exercise (early exercise group). The other 40 participants will continue with their normal
activities for 16 weeks (delayed exercise group). After the 16 week period, participants in
the delayed exercise group will take part in the 8-week supervised exercise program.
Exercise sessions will take place at selected YMCAs in Edmonton and Calgary. Exercise
sessions will be supervised by specially trained exercise specialists who have received
special training in exercise and cancer.
Outcomes of the study will include feasibility, physical fitness measures, cancer-related
symptoms and quality of life.
| Status | Completed |
| Enrollment | 80 |
| Est. completion date | June 30, 2018 |
| Est. primary completion date | December 2016 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: 1. Within 18 months of a diagnosis of any type of cancer 2. Receiving or have received curative cancer treatment (e.g., surgery, chemotherapy, radiation therapy) 3. Cleared for unrestricted physical activity by their treating oncologist Exclusion Criteria: 1. Presence of metastatic disease 2. Any uncontrolled or serious comorbid conditions that would preclude participation in exercise testing and training 3. Women who are pregnant |
| Country | Name | City | State |
|---|---|---|---|
| Canada | University of Calgary/ Tom Baker Cancer Centre | Calgary | Alberta |
| Canada | University of Alberta/ Cross Cancer Institute | Edmonton | Alberta |
| Lead Sponsor | Collaborator |
|---|---|
| University of Alberta | AHS Cancer Control Alberta, University of Calgary |
Canada,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Other | Adverse Events rate | Number of serious and minor adverse events | 24 weeks | |
| Other | Program Costs | Costs related to study personnel, fitness centre costs and participant related costs | 24 months | |
| Other | Body composition | Body mass index | 8 weeks | |
| Primary | Feasibility: number of participants completing the objective outcome measurements for the study | Proportion of subjects completing the physical fitness tests including aerobic capacity, musculoskeletal fitness and body composition measurements. | 24 weeks | |
| Secondary | Aerobic Capacity | Change in submaximal aerobic exercise capacity (treadmill, bike or 6 minute walk test) | 8 weeks | |
| Secondary | Health-related Quality of Life | Change in quality of life: Functional Assessment of Cancer Therapy General Questionnaire | 8 weeks | |
| Secondary | Symptom Assessment | Change in symptoms: Memorial Symptom Assessment Scale | 8 weeks | |
| Secondary | Adherence to exercise | Attendance at supervised exercise sessions | 24 weeks | |
| Secondary | Recruitment rate | Number of participants consenting to the study divided by the number of eligible participants | 18 months | |
| Secondary | Upper Extremity Muscular Strength (optional) | Change in 8 repetition maximum strength of chest press | 8 weeks | |
| Secondary | Upper Extremity Grip Strength (optional) | Hand Grip strength | 8 weeks | |
| Secondary | Lower Extremity Muscular Strength (optional) | Change in 8 repetition maximum strength of leg press | 8 weeks |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03826043 -
THrombo-Embolic Event in Onco-hematology
|
N/A | |
| Terminated |
NCT03166631 -
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
|
Phase 1 | |
| Completed |
NCT01938846 -
BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT06058312 -
Individual Food Preferences for the Mediterranean Diet in Cancer Patients
|
N/A | |
| Completed |
NCT03308942 -
Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants
|
Phase 2 | |
| Recruiting |
NCT06018311 -
Exercising Together for Hispanic Prostate Cancer Survivor-Caregiver Dyads
|
N/A | |
| Withdrawn |
NCT05431439 -
Omics of Cancer: OncoGenomics
|
||
| Completed |
NCT01343043 -
A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma
|
Phase 1 | |
| Completed |
NCT01938638 -
Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer
|
Phase 1 | |
| Recruiting |
NCT05514444 -
Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001)
|
Phase 1 | |
| Recruiting |
NCT02292641 -
Beyond TME Origins
|
N/A | |
| Terminated |
NCT00954512 -
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04958239 -
A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors)
|
Phase 1 | |
| Recruiting |
NCT04627376 -
Multimodal Program for Cancer Related Cachexia Prevention
|
N/A | |
| Completed |
NCT01222728 -
Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
|
||
| Recruiting |
NCT06004440 -
Real World Registry for Use of the Ion Endoluminal System
|
||
| Active, not recruiting |
NCT05636696 -
COMPANION: A Couple Intervention Targeting Cancer-related Fatigue
|
N/A | |
| Not yet recruiting |
NCT06035549 -
Resilience in East Asian Immigrants for Advance Care Planning Discussions
|
N/A | |
| Recruiting |
NCT06004466 -
Noninvasive Internal Jugular Venous Oximetry
|
||
| Completed |
NCT02909348 -
Immunophenotyping of Melanoma Patients on Treatment With Pembrolizumab
|